Melanoma is one of the most lethal forms of skin cancer because of its early metastatic spread. The variant form of CD44 (CD44v), a cell surface glycoprotein, is highly expressed on metastatic melanoma. The mechanisms of regulation of CD44 alternative splicing in melanoma and its pathogenic contributions are so far poorly understood. Here, we investigated the expression level of CD44 in a large set of melanocytic lesions at different stages. We found that the expression of CD44v8-10 and a splicing factor, U2AF2, is significantly increased during melanoma progression, whereas CD82/KAI1, a tetraspanin family of tumor suppressor, is reduced in metastatic melanoma. CD44v8-10 and U2AF2 expression levels, which are negatively correlated with CD82 levels, are markedly elevated in primary melanoma compared with dysplastic nevi and further increased in metastatic melanoma. We also showed that patients with higher CD44v8-10 and U2AF2 expression levels tended to have shorter survival. By using both in vivo and in vitro assays, we demonstrated that CD82 inhibits the production of CD44v8-10 on melanoma. Mechanistically, U2AF2 is a downstream target of CD82 and in malignant melanoma facilitates CD44v8-10 alternative splicing. U2AF2-mediated CD44 isoform switch is required for melanoma migration in vitro and lung and liver metastasis in vivo. Notably, overexpression of CD82 suppresses U2AF2 activity by inducing U2AF2 ubiquitination. In addition, our data suggested that enhancement of melanoma migration by U2AF2-dependent CD44v8-10 splicing is mediated by Src/focal adhesion kinase/RhoA activation and formation of stress fibers, as well as CD44-E-selectin binding reinforcement. These findings uncovered a hitherto unappreciated function of CD82 in severing the linkage between U2AF2-mediated CD44 alternative splicing and cancer aggressiveness, with potential prognostic and therapeutic implications in melanoma.
INTRODUCTION
Melanoma is one of the most deadly and malignant tumors with high propensity to metastasize to distant organs. 1, 2 Previously, it was shown that metastatic melanoma cells possess aberrantly high levels of CD44v on their surface that can be associated with E-selectin on endothelium to mediate cell adhesion in flow and induce endothelial junction breakdown. [3] [4] [5] CD44 is a glycoprotein displaying size heterogeneity because of alternative splicing and differential posttranslational glycosylations. 6 Standard CD44 (CD44s) is generated by splicing out all variable exons, whereas variant forms of CD44 (CD44v) are created by selectively including multiple variant exons (exons [6] [7] [8] [9] [10] [11] [12] [13] [14] . The isoform switching from CD44s to CD44v in response to certain stimuli confers metastatic potentials on tumors. The process of CD44v pre-mRNA splicing is composed of spliceosome complex assembly favoring inclusion of variant exons. 7 It has been shown that CD44 variable exon splicing is mediated by epithelial splicing regulatory protein (ESRP) in immortalized epithelial cells, breast cancer and head and neck carcinoma cells. [8] [9] [10] ESRP1 and ESRP2 were shown to regulate splicing of v8-v10 and v6-v10 exons of CD44, maintaining cell epithelial phenotypes. 11 Other splicing factors, like Tra2β and SRm160, also mediate CD44 alternative splicing in gastric epithelial cells and Hela cells. 12, 13 It was recently reported that primary melanoma with tendency for brain metastasis expresses high levels of CD44v6. Splicing factors, ESRP1, ESRP2, PTBP1 and U2 snRNP auxiliary factor (U2AF2), correlate with CD44v6 expression in primary melanoma, and ESRP1 knockdown in melanoma cells resected from lymph node metastases decreases CD44v6 expression. Despite all these discoveries, very little is known about the functional roles of splicing factors in melanoma metastasizing to other organs, especially lung and liver, and the exact mechanisms of CD44 splicing in melanoma.
The KAI1/CD82, first identified as a tumor suppressor in prostate cancer, is a member of the tetraspanin superfamily with a wide spectrum of biological functions.
14 Studies demonstrated that CD82 limits tumor progression and metastasis in a number of ways. CD82 can inhibit cell motility by reorganizing specific tetraspanin-enriched web, called TERM. 15 TERM facilitates CD82 association with various receptors and cytoplasmic signaling molecules, modulating lateral cross-talk in the plasma membrane. 16 CD82 can be associated with epidermal growth factor receptor and regulate its ubiquitylation, thereby inhibiting communications between heparin sulfate proteoglycans and ligand-bound epidermal growth factor receptor. 17 The modulatory effect of CD82 is also dependent on trafficking of CD82 in endocytic organelles, such as late endosomes and lysosomes. 17, 18 Noteworthy, CD82 participates in regulating angiogenesis by disturbing the interaction among CD44, ganglioside and lipid rafts, leading to enhanced clathrin-independent endocytosis of CD44. 19 Nevertheless, it is unknown whether CD82 regulates melanoma migration by altering the structure and function of CD44. In this study, we demonstrated that ectopic expression of CD82 in metastatic melanoma reduces tumor migration and spontaneous metastasis by decreasing the ratio of CD44v to CD44s. In addition, CD82 inhibits CD44 alternative splicing by inducing U2AF2 ubiquitination.
RESULTS
CD44v8-10 is upregulated during melanoma progression and correlated with poor prognosis CD44 variant isoforms are upregulated in cancer stem cell-like cells and advanced cancer, having roles in tumor adhesion, hemato`genous metastasis, drug resistance and tumorigenesis. 6, [20] [21] [22] [23] To identify the CD44 isoform present on malignant melanoma, real-time PCR was used to measure variable exon selections in Lu1205M, A375M, 2 SK-Mel-25 and WM35 cells with different metastatic potentials (Table 1) , as well as normal human epidermal melanocytes (NHEMs). Lu1205M cells were derived from Lu1205 cells 4 and underwent extensive aggressiveness selection. Therefore, Lu1205M cells exhibited high malignant and metastatic properties with elevated potentials for colonizing lungs and livers (Table 1) . Real-time PCR revealed that SK-Mel-25 cells expressed appreciable amounts of CD44s but low levels of variable exons, whereas exons 12-14 (v8-v10) were selectively expressed on A375M and Lu1205M cells (Figure 1a ). The performance of each primer set was evaluated with CD44v2-10-expressing keratinocyte HaCaT cells. All primer sets efficiently amplified target exons in HaCaT mRNA (Supplementary Figure 1A) . PCR results were validated with western blotting (2C5 antibody), which demonstrated that NHEM and WM35 do not express any CD44 molecules, SK-Mel-25 only expresses CD44s yielding an intense 100 kD band, A375M expresses the 100 kD CD44s and a 150 kD protein, and high levels of the 150 kD protein were also detectable on Lu1205M cells (Figure 1b) . PCR results motivated us to surmise that the 150 kD protein is CD44v8-10. To verify the status of the protein, we generated a CD44v8-10 epitope-specific antibody ( Supplementary Figures 2A and B) . This antibody specifically recognized the 150 kD protein without any crossreactivity with other proteins on Lu1205M and A375M cells, suggesting that the protein is CD44v8-10 ( Figure 1c ). The lack of reactivity of VFF-18 toward any epitopes in SK-Mel-25, A375M and Lu1205M samples implies that melanoma cells do not express detectable amounts of CD44v6 protein (Supplementary Figure 3A) . A more precise determination of the exon composition of variant isoforms was achieved by the run-off analysis, which verified the continuous alignment of v8, v9 and v10 exons up to CD44v8-10 (729 bp) in the transcripts from Lu1205M and A375M cells, whereas the predominant isoform on SK-Mel-25 cells was CD44s (268 bp) (Figure 1d ). As a positive control, exon-specific primers used in the run-off analysis detected CD44v2-10, CD44v6-10 and CD44v8-10, which are the major CD44v isoforms being expressed by HaCaT (Supplementary Figure 1B) .
To evaluate the clinical implication of molecular alteration of CD44, we analyzed melanoma patient tissue samples ( Table 2) . We included melanoma in situ, which is designated as TNM stage 0 (TisN0M0) into our analysis. In 70 melanoma patients, CD44v8-10 staining was not correlated with age and gender, whereas it was significantly correlated with tumor differentiation status and TNM stages. Strong CD44v8-10 expression was found in 20% and 40% cases with stage I and II, whereas 73% and 80% of stage III and IV melanoma had strong CD44v8-10 expression. CD44v8-10 staining intensity increased in primary melanoma compared with dysplastic nevi and further rose in metastatic melanomas (P o 0.001) (Figure 2a ). Nevi, primary melanoma and metastatic melanoma showed a weak expression of CD44v6 (Supplementary Figure 3B) . No significant difference in staining intensity of CD44v6 was found in nevi compared with primary and metastatic melanoma (P40.05). In analysis of Kaplan-Meier survival curves, we found that elevated CD44v8-10 was significantly correlated with a poorer overall survival of all melanoma patients (Figure 2c ). These data suggest that elevated CD44v8-10 may have pathological roles in melanoma metastasis.
CD82 prevents CD44s/CD44v8-10 isoform switch in melanoma Previously, it was reported that endothelial CD82 inhibited the cell surface presence of CD44. 19 Furthermore, downregulation of CD82 is common in advanced human cancer. 24 Therefore, we examined the effect of modulation of CD82 expression on CD44 isoform expression in melanoma. Compared with WM35, Lu1205M expresses low levels of CD82 (Figure 3a) . When CD82 was overexpressed in Lu1205M, CD44v8-10 was reduced and CD44s Cell invasiveness was measure with transwell assay in a 24-well plate (Corning). In all, 8 μm pore transwell membrane was coated with 1 mg/ml of Matrigel (BD Biosciences, San Jose, CA, USA). The lower chamber was filled with 20% fetal bovine serum (FBS) as chemoattractant. Cells were allowed to migrate for 24 h.
b Cell chemotaxis was determined with a 48-well Boyden chamber with IV collage as chemoattractant. Number of migrated cells were stained with crystal violet and visualized with microscopy. upregulated at both mRNA and protein levels (Figures 3a and b and Supplementary Figures 4A and B) . Conversely, knockdown of endogenous CD82 with small interfering RNA (siRNA) in SK-Mel-25 resulted in a remarkable increase in CD44v8-10 and a concomitant reduction of CD44s expression (Figures 3c and d) . These results suggest that CD82 functions as an important regulator to suppress the isoform switch from CD44s to CD44v.
Then, we determined the association between CD82 and CD44v8-10 expression in clinical samples. CD82 level tended to drop as the TNM staging advanced and high abundance of CD82 correlated with a better relapse-free survival (Figure 2b ). In addition, CD82 expression was negatively correlated with levels of CD44v8-10 as detected by CD44v8-10 antibody and commercial CD44v7/8, CD44v9 and CD44v10 antibodies (P o 0.001, R = 0.76) (Figure 2b and Supplementary Figure 5 ).
Splicing factor U2AF2 promotes CD44 alternative splicing in metastatic melanoma To investigate whether CD82 suppresses CD44v8-10 expression through regulation of splicing, we silenced a set of splicing factors, Tra2β, SRp20, ESRP1, YB-1, SRm160, Sam68 and U2AF2, which have been shown to mediate CD44v splicing. 10, 12, 13, 25, 26 Only knockdown of U2AF2 markedly reduced CD44v8-10 expression (Supplementary Figure 6) . Of five cell lines, U2AF2 expression was associated with metastatic potentials with the highest level found on Lu1205M (Figure 4a ). U2AF2 knockdown with short hairpin RNA (shRNA) significantly increased CD44s and attenuated CD44v8-10 expression levels (Figures 4b and c, Supplementary  Figures 4C and D) . Then, we generated a shRNA-resistant U2AF2 construct, which contains three mutated nucleotides, in shRNA Abbreviation: TNM, tumor-node-metastasis staging classification system. From National Comprehensive Cancer Network (NCCN) guidelines. a CD44 expression was scored according to both staining intensity and percentage of CD44v8-10-positive cells, which were evaluated in a blinded manner by three independent observers. CD44v8-10 expression was scored as -(negative), + (weak), ++ (moderate) and +++ (strong).
b P-value when expression levels were compared using Mann-Whitney test. c P-value when expression levels were compared using Kruskal-Wallis test.
Suppression of U2AF2-mediated CD44v splicing by CD82 P Zhang et al seeding region without changing amino-acid sequence ( Figure 4b , upper panel). 27 Overexpression of shRNA-resistant U2AF2 in U2AF2-silenced Lu1205M rescued CD44v8-10 expression, suggesting that U2AF2 is the splicing factor mediating CD44s/CD44v isoform switch ( Figure 4b , middle and lower panels). To further evaluate the role of U2AF2 in CD44 alternative splicing, U2AF2 construct was transfected into SK-Mel-25 cells, which expressed low levels of this splicing factor. Overexpression of U2AF2 triggered CD44v8-10 expression at both mRNA and protein levels (Figures 4d and e) .
To gain more insight into the molecular basis for the function of U2AF2 in regulating CD44 splicing, we utilized a minigene with pFlare-RFP/GFP reporter system, 28 where start codon for GFP is split by inserting V8-10 exon and its flanking introns. This insertion results in GFP expression when V8-10 exon is skipped and RFP synthesis when it is included. Our results showed that RFP was dominantly expressed, suggesting that CD44v8-10 is spliced in control Lu1205M (Figure 4f ). In contrast, knockdown of U2AF2 in Lu1205M attenuated RFP signal and increased GFP expression. Knockdown of U2AF2 in Lu1205M and A375M promoted exon skipping and significantly reduced the ratio of V8-10 exon splicing/exclusion (Figures 4g-i ). U2AF2 can bind to weak polypyrimidine tract in 3'-splicing site to facilitate exon splicing. 26 To find whether 3'-splicing site of V8-10 contains U2AF2 response element, we introduced mutations in 3' polypyrimidine tract. Point mutations from CT to AA at -4 and -5 positions sharply comprised the stimulative effect of U2AF2 on V8-10 splicing (Figures 4j and k) . These results imply that by targeting 3' polypyrimidine tract, U2AF2 enforces CD44v8-10 splicing in melanoma.
U2AF2 participates in CD82-mediated CD44 alternative splicing To demonstrate that U2AF2 is under control of CD82 to mediate CD44 splicing, U2AF2 expression was examined in Lu1205M following CD82 overexpression. Ectopic expression of CD82 in Lu1205M diminished U2AF2 expression (Figure 5a ). On the other hand, knockdown of CD82 by siRNA in SK-Mel-25 resulted in an increased expression of U2AF2 ( Figure 5b) . Surprisingly, although CD82 knockdown in Lu1205M and A375M induced a marked change of protein levels of U2AF2, mRNA levels did not correlate with this change (Figure 5c ). Therefore, CD82 may modulate U2AF2 activities at posttranslational level. Accordingly, we tested the hypothesis that CD82 reduces U2AF2 protein stability by inducing its ubiquitination. Our results showed that CD82 increased U2AF2 ubiquitination in a dose-dependent manner in both Lu1205M and A375M ( Figure 5d ).
As with CD44v8-10, enhanced expression of U2AF2 was observed during clinical melanoma progression (Figure 2a ). U2AF2 level was drastically increased in primary melanoma compared with dysplastic nevi (Po 0.001) and further upregulated in metastatic melanoma (P o 0.001). In addition, decreased U2AF2 Figure 2 . CD44v8-10 expression is positively correlated with U2AF2 expression and negatively correlated with CD82 level in metastatic melanoma tissues. (a) Analysis of expression levels of CD44v8-10 and U2AF2 with immunohistochemistry (IHC) in nevi from 6 non-melanoma patients and 12 samples of melanoma in situ and metastatic melanoma from melanoma patients. Protein levels were quantified in formalinfixed paraffin-embedded tissue (FFPE) tissue samples. Mann-Whitney U-test was used. (b) The correlation between CD82 relative expression levels (log transformed) and CD44v8-10 relative expression levels (log transformed) in 70 FFPE melanoma tissue samples from patients with clinical TNM stage 0-IV. Pearson's R test was used. R-and P-values are calculated as indicated. (c) Association between CD44v8-10 and U2AF2 expression and survival of melanoma patients (n = 70). The melanoma patients were stratified according to CD44v8-10 and U2AF2 expression levels into high and low groups. Patients expressing high CD44v8-10 and U2AF2 levels displayed significantly shorter survival (log-rank test).
staining was strongly associated with a better patient survival (Figure 2c ). The 5-year survival rate dropped from 75% in patients with low U2AF2 expression to 48% in those with positive U2AF2 expression. There was a significant negative correlation between CD82 and U2AF2 levels in melanoma samples (Figure 2b) . Altogether, these results suggest that in metastatic melanoma, downregulation of CD82 expression elevated U2AF2 expression, which increased the ratio of CD44v8-10 to CD44s. CD82 inhibits melanoma motility by interfering U2AF2-mediated CD44v8-10 splicing As CD44v isoform expression in cancer may contribute to tumor adhesion, migration and metastasis, we next assessed the roles of CD82 in CD44v8-10-dependent cell motility. 6, 29 Overexpression of U2AF2 significantly enhanced SK-Mel-25 migration (Figure 6a) . However, the pro-migratory effect of U2AF2 can be attenuated by CD44v8-10 shRNA but not by CD44s shRNA. When endogenous CD82 in SK-MEL-25 were inhibited, cell migration was enhanced by fivefold (Figure 6b ). Knockdown of U2AF2 or CD44v8-10 markedly reduced the migration potentials of SK-Mel-25/siCD82 cells. Either knockdown of U2AF2 or overexpression of CD82 in Lu1205M suppressed Lu1205M motility (Figures 6c and d) . Restoration of CD44v8-10 but not CD44s rescued the suppressive effect of shU2AF2 on melanoma migration (Figure 6c) . Similarly, migratory potentials of Lu1205M/CD82 were increased by reconstitution of U2AF2 or CD44v8-10 ( Figure 6d) . A lack of involvement of CD44v6 in melanoma migration was evident as knockdown of CD44v6 did not affect Lu1205M migration (Supplementary Figure 3C) . These results suggest that CD82 suppresses melanoma motility through regulating U2AF2 expression and CD44s/CD44v8-10 isoform switching.
Flow-regulated cancer migration has important roles in tumor metastasis. To evaluate the roles of CD82-regulated CD44 splicing on melanoma migration under hydrodynamic conditions, we utilized a flow migration assay. 1, 30 At a shear stress of 0.625 dyn/cm 2 but not 2 dyn/cm 2 , knockdown of endogenous U2AF2 or overexpression of CD82 reduced the transendothelial migration of Lu1205M (Figures 6e and f) . Conversely, restoration of CD44v8-10 but not CD44s abrogated the U2AF2 knockdowndependent reduction in melanoma extravasation (Figure 6e ). The suppressive effect of CD82 overexpression on melanoma migration in flow was rescued by transfection of U2AF2 or CD44v8-10 ( Figure 6f ). Therefore, CD44v8-10 may contribute to melanoma migration under low shear conditions.
Cell tethering mediated by reversible interactions between selectins and sialyl-Lewis X -decorated receptors on tumor surface is the first step for tumor metastasis. 31, 32 To determine the effect of CD44 isoform switching on tumor adhesion, we assessed binding frequency between E-selectin and melanoma with a micropipette aspiration assay (Figure 7a ). Upon 5-s contacts, CD44s-expressing SK-Mel-25 adhered more frequently to E-selectin compared with WM35 or NHEM (P o 0.05) (Figure 7b ). CD44v8-10-expressing A375M or Lu1205M had higher affinity for E-selectin than SK-Mel-25 (P o 0.05). Overexpression of CD82 or knockdown of U2AF2 or CD44v8-10 sharply diminished the adhesion probability of Lu1205M (Figure 7c) . Interestingly, the difference of adhesion probability among different cell lines was not observed for short contact duration (2.5 s) (Figures 7b and c) .
In migrating Lu1205M, robust stress fiber structures formed with thick actin filaments traversing the cell bodies (Figure 8a) . In sharp contrast, ectopic expression of CD82 disrupted the stress fiber structure with only thin filaments visible in the cell peripheries. Similarly, silencing U2AF2 or CD44v8-10 abolished actin polymerization. By staining paxillin, a scaffold adaptor protein localized in focal adhesion, it was demonstrated that control cells had bright punctate focal adhesion associated with the ends of thick stress fibers. But overexpression of CD82 or knockdown of U2AF2 or CD44v8-10 reduced the size and number of focal adhesions where paxillin spots disengaged with actin (Figures 8a-c) . Then, the activation status of migratory machinery, including focal adhesion kinase (FAK), Src and RhoA, was assessed. CD82 overexpression or knockdown of U2AF2 or CD44v8-10 suppressed the phosphorylation of FAK and Src and GTP coupling of RhoA without affecting total FAK, Src and RhoA levels (Figure 8d ).
CD82 targets U2AF2-mediated CD44v8-10 splicing to inhibit melanoma metastasis in vivo To assess whether modulation of CD82, U2AF2, CD44s and CD44v8-10 expression could affect melanoma metastasis in vivo, we used two metastatic models: xenograft liver metastasis and experimental lung metastasis. Compared with control groups, xenograft tumors derived from CD82-overexpressing, U2AF2-silenced and CD44v8-10-silenced Lu1205M metastasized less efficiently to the liver 20 days after subcutaneous implantation (Figure 9a ). CD82 overexpression, U2AF2 knockdown or CD44v8-10 knockdown reduced the number of metastatic lesions by 80%. On the contrary, CD44s knockdown did not significantly reduce Lu1205M liver metastasis compared with control. To determine whether melanoma tumorigenesis was affected, size of primary tumors was measured on alternative days up to 19.5 days. Overexpression of CD82 or knockdown of U2AF2 or CD44v8-10 did not alter the rate at which Lu1205M tumors grew in comparison with control (Figure 9b) . Thus, CD82-regulated CD44v8-10 splicing had no effect on melanoma tumorigenesis. 
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Hematoxylin and eosin staining verified tumor nodule quantification results for involvement of CD82, U2AF2 and CD44v8-10 in melanoma liver metastasis (Figure 9c ). In tumor-migrating fronts, CD44v8-10 was localized in cell membrane, whereas U2AF2 exhibited a nucleus and cytoplasma staining pattern (Figure 9d ). CD44s was absent from tumor-migrating fronts. CD82 overexpression or U2AF2 knockdown reduced the robust staining for CD44v8-10 and U2AF2, whereas CD44s levels were increased ( Figure 9d ). As for experimental lung metastasis, Lu1205M-LUC/CD82 cells migrated less efficiently than control cells (Supplementary Figures 7A and B) . Further, overexpression of U2AF2 or CD44v8-10 rescued tumor lung metastasis. Notably, inoculation of Lu1205M-LUC co-transfected with CD82 and CD44v8-10 resulted in even more lung seedings than Lu1205M-LUC/vector melanoma. Western blot analysis demonstrated lower expression levels of CD44v8-10 and U2AF2 in CD82-expressing lung metastases in comparison with control (Supplementary Figure 7C) . Reconstitution of U2AF2 expression in CD82-expressing melanomas rescued the suppressed CD44v8-10 expression. Restoring CD44v8-10 in melanoma did not alter the expression levels of U2AF2 and CD44s, indicating that CD44v8-10 is located in the downstream of U2AF2. Our findings suggest that CD82 suppresses melanoma metastasis in vivo by inhibiting U2AF2-dependent CD44v8-10 splicing.
DISCUSSION
Our study revealed that CD44v8-10 is not only a prognostic marker but also a functional receptor for melanoma metastasis. In agreement with earlier studies, our results showed that elevated level of CD44v8-10 is associated with tumor metastatic potentials. 11 It was reported that CD44v8-10 splicing promotes tumorigenesis by driving stem cell-like properties. 25, 33 In this study, our findings provided novel evidence for the role of CD82 in regulating pre-mRNA splicing in melanoma and proposed a mechanism by which CD82 suppresses melanoma metastasis by modulating U2AF2-dependent CD44v8-10 splicing (Figure 10 ). This hypothesis is supported by: (1) overexpression of CD82 in highly metastatic melanoma reduces the ratio of CD44v8-10 to CD44s; (2) CD82 regulates U2AF2 protein stability by facilitating its ubiquitination; (3) overexpression of CD82 in melanoma impedes tumor migration under static and flow conditions, which can be rescued by restoration of U2AF2 or CD44v8-10 expression; (4) the suppressive effect of CD82 on tumor migration is dependent on altered affinity of CD44 for selectin, inactivation of Src/FAK/RhoA, and disassembly of stress fibers and focal adhesions.
A marked decrease in CD82 expression is one of the characteristics of late-stage human cancers. 14 The function of CD82 in impeding cancer motility and invasion may be related to modulating the activity of receptor tyrosine kinases, inhibiting p130CAS-CrkII coupling, and suppressing integrin-dependent cross-talk with c-Met and Src. 34, 35 Strikingly, a previous study showed that upon association with Duffy antigen receptor group (DARC), CD82 limits melanoma invasion by disrupting IL-8-mediated VE-cadherin disassembly. 36 It was also shown that CD82 reduces epidermal growth factor receptor ubiquitination and alters the kinetics of the recruitment of receptors to early endosomes. 17 The relationship between CD82 and CD44 was explored by a recent study showing that CD82 reduces endothelial migration by suppressing lipid raft formation and enhancing endocytosis of CD44. 19 It is unlikely that CD82 directly regulates spliceosome, as it lacks enzymatic motifs in its cytoplasmic tails.
14 Instead, CD82 may be associated with integrins in tetraspanin web to regulate integrin signaling. In agreement with this, the role of integrins in gene splicing has been documented in that α 3 β 1 integrin induces COX-2 alternative splicing in breast cancer. 37 Disruption of exon recognition and misregulation of alternative splicing are a common cause of human disease. In this study, we showed that CD44v8α10 splicing was U2AF2 dependent, as the minigene system reported a significant reduction of V8α10 splicing following U2AF2 knockdown. The essential pre-mRNA Figure 7 . U2AF2-mediated CD44 isoform switching increases the affinity of tumor CD44 for E-selectin. Binding affinity of melanoma cells for E-selectin was analyzed by the micropipette assay. (a) Schematic representation of the dual micropipette setup. A CD44-expressing tumor cell and an E-selectin-coated RBC were held by two opposing micropipettes and allowed to contact for different time durations. Binding events were recorded by analyzing the deflection of RBC membrane. (b) Adhesion frequency of melanoma to E-selectin upon receptor/ligand contact for 5 s was increased progressively with increasing metastatic potentials. (c) Lu1205M cells were transfected with vector, CD82, scrambled shRNA, shU2AF2 or shCD44v8-10 and allowed to contact with E-selectin coated RBC for 2.5 and 5 s before binding frequency was measured. Values are shown as mean ± s.e.m. from six independent experiments. *P o0.05. splicing factor, U2AF2, is a non-snRNP protein required for binding U2 snRNP to pre-mRNA. 38 Recruitment of U2AF2 to 3'-splicing site is a primary determinant for exon selection and the initiation of prespliceosome complex formation. 38 It was shown that U2AF2 expression in melanoma tissue samples is correlated with CD44v6/ s ratio. 39 Although ESRP1 has been reported in multiple epithelial tumors to promote CD44v8-10 splicing, in mesenchymal-type melanoma cells, like Lu1205M, ESRP1 was barely detectable (data not shown). Thus, ESRP1 may be dispensable for CD44 splicing in late-stage melanoma. It was reported that YB-1 may assist exon inclusion of CD44v by enhancing the recruitment of U2AF2 to weak polypyrimidine tracts. 26 Therefore, it is of interest to investigate whether other splice factors participate in U2AF2-induced CD44v8-10 splicing in the future studies.
Posttranslational modifications, including phosphorylation and ubiquitination, are implicated in modulation of activities of a number of splicing factors, allowing fine tuning of the splicing reactions.
40 SF2/ASF protein can be phosphorylated by Cdc2 kinase in a cell cycle-dependent manner to regulate spliceosome function. 41 Serine/threonine kinase, Plk1, interacts with splicing factor, UAP56, triggering its phosphorylation, ubiquitination and degradation through proteasomes. 42 A more recent report showed that dopamine and cyclic adenosine monophosphateregulated phosphoprotein (DARPP-32) interacts and stabilizes SRp20, thereby increasing its splicing activity and CD44v8-10 expression. 25 In the presence of DARPP-32, SRp20 ubiquitination is inhibited, highlighting the importance of ubiquitination in controlling splicing factor activities. In this study, CD82 may utilize some indirect pathways to activate ubiquitin ligases, which induce ubiquitination and degradation of U2AF2. 14 Tumor extravasation in blood stream requires cell rolling and tethering mediated by Sialyl-Lewis X -decorated receptors followed by integrin-mediated stable adhesion. 22, 43 It was widely accepted that CD44v rather than CD44s binds to selectin in flow to promote colon and breast cancer rolling and tethering. 44 In agreement with these studies, our micropipette aspiration assay revealed that CD44v8-10 on metastatic melanoma cells has higher affinity for E-selectin than CD44s. Owing to the presence of variant regions, CD44v has greater molecular length and more glycosaminoglycan modifications, which facilitate bond formation with selectins compared with CD44s. 6 Therefore, the pro-migratory effect of U2AF2-dependent CD44 splicing may be attributed to diverse affinities of CD44v8-10 and CD44s for E-selectin. As CD44v has a higher affinity for E-selectin than CD44s, a isoform switching from CD44s to CD44v8-10 can serve as an effective receptor for circulating melanoma to be captured by endothelium under physiological flow conditions. 32 On the other hand, by tethering to selectins, CD44v8-10 may also function as a signaling platform mediating mechanosensor docking to activate integrin, which further enhances melanoma migration. 45 This is supported by the observation that CD44v8-10 is important for melanoma motility by promoting stress fiber formation and focal adhesion assembly.
In conclusion, we demonstrated that CD82 controls melanoma metastasis by suppressing U2AF2-mediated CD44 alternative splicing. The CD82-U2AF2 axis may be critical for regulating CD44v8-10 splicing that promotes melanoma metastasis. Our work provides rationales for further exploration of these molecules as therapeutic targets to treat melanoma metastasis.
MATERIALS AND METHODS

Cell culture
NHEMs (obtained from PromoCell, Heidelberg, Germany) were cultured in melanocyte growth medium. Lu1205M and A375M, highly metastatic variants of melanoma cell lines, Lu1205 and A375 (ATCC, Manassas, VA, USA), were derived by in vivo injecting Lu1205 and A375 cells into nude mice and, 25 days later, establishing cell lines from tumors, which had formed in the lungs. Cells were maintained in Dulbecco's modified Eagle's medium (GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 100 U/ml of penicillin-streptomycin. SK-Mel-25 (ATCC) and WM35 melanoma cells (provided by Dr Meenhard Herlyn, Wistar Institute, Philadelphia, PA, USA) were maintained in Roswell Memorial Park Institute (RPMI) supplemented with 10% fetal bovine serum and 100 U/ml of penicillin-streptomycin. All cells were maintained in a humidified incubator at 37°C and 5% CO 2 .
Human tissue samples
Tissue collection and analysis in this study were approved by the ethics committee of Third Military Medical University of China, and written informed consent was obtained from all participants. Formalin-fixed paraffin-embedded tissue sections of 6 dysplastic melanocytic nevi, 19 primary melanomas and 51 metastatic melanomas samples were collected. All clinicopathological data are made available for all melanoma cases. The 70 melanoma patients consist of 32 females and 38 males, aging 18-83 years (median, 53 years). Cases were selected from original hematoxylin and eosin stainings. The differences of variables, like age and sex, among TNM stages are statistically insignificant.
Xenograft tumor model
All the procedures involving animals were reviewed and approved by Pennsylvania State University Institutional Animal Care and Use Committee. For orthotopic metastasis assay, 5-week-old athymic nu/nu male Balb/c mice (Herlan, Indianapolis, IN, USA) were randomized in different groups and implanted subcutaneously in the right flank with Lu1205M cells (1 × 10 6 cells/100 μl phosphate-buffered saline/Matrigel). Ten successful tumor xenografts were utilized in each group, according to statistical analysis of sample size. Evaluation of tumor size and metastatic tumor loci was conducted by two independent investigators who were blinded to the study groups. The tumor size was measured by caliper. After 20 days, there were no significant differences of primary tumor weight among groups (data not shown). To examine the tumor metastasis, the livers in each group were collected and submitted in 4% neutral buffered formalin. Six sections through the center of the liver were examined under dissecting microscopy for presence of metastases and the number of metastases per section was determined. In selected cases, the tumor tissues were fixed in formalin and embedded in paraffin for immunohistochemistry and routine hematoxylin and eosin staining. 
Immunohistochemistry
Polyclonal antibodies against CD44v8-10 molecule were generated and purified as described previously. 46, 47 Briefly, New Zealand White female rabbits were immunized with a GST-CD44v8-10 fusion protein, and the resulting anti-CD44v8-10 antibody was immunoaffinity purified with a GST-CD44v8-10 affinity column. Formalin-fixed paraffin-embedded tissue from patient and mouse samples were incubated with commercial antibodies, anti-CD44v7/8 (VFF-17, Serotec, Inc., Raleigh, NC, USA), CD44v9 (11.24, IgG 1), CD44v10 (Millipore, Billerica, MA, USA), U2AF2 (Abcam, Eugene, OR, USA) or CD82 (Novus Biologicals, Littleton, CO, USA) or immunopurified anti-CD44v8-10. Then, the samples were incubated with horseradish peroxidase-conjugated secondary antibodies (Abcam). The target proteins were detected with 3,3′diaminobenzidine. Nuclei were counterstained with hematoxylin. The gray values of staining were quantified with ImageJ (Bethesda, MD, USA).
Complementary DNA transfection
Complementary DNA clones of CD44s, CD44v8-10, hemagglutinin-tagged CD82 and GST-tagged U2AF2 (Origene, Rockville, MD, USA) were inserted into the expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). In all, 200 ng CD44s, CD44v8-10, U2AF2, CD82 or pcDNA3.1 vector control constructs were transfected into cells with Mirus TransIT (Mirus Bio LLC, Madison, WI, USA) and then subjected to G418 selection for 2-3 weeks.
Silencing CD82, U2AF2, CD44s and CD44v8-10 with siRNA or shRNA siRNA targeting CD82 and si/shRNA transfection were described previously. 36 siRNA oligonucleotides targeting U2AF2, CD44s or CD44v8-10 were synthesized (Life Technologies, Carlsbad, CA, USA) and ligated into pSUPER.neo.gfp expression vector (Oligoengine, Inc., Seattle, WA, USA). The following oligonucleotides were used (underlined, sense and antisense sequences; bold, restriction enzyme sites; light italics, polIII termination signals; bold italics, loop with linker): CD44v8-10, 5′-GATCCCCGGAA GAAGATAAAGACCATTTCAAGAGAATGGTCTTTATCTTCTTCCTTTTTC-3′; CD4 4s, 5′-GATCCCCCCTGCTACCAGAGACCAAGTTCAAGAGACTTGGTCTCTGGTA GCAGGTTTTTC-3′; U2AF2, 5′-GATCCCCGCACGGTGGACGATTCGTTTCAAGA GAACGAATCGTCCACCGTGCTTTTTC-3′. A tested scrambled sequence (Life Technologies) was used as a negative control.
Construction of pFlare-v8-10 minigene A reporter construct was generated using standard cloning techniques. The CD44 genomic DNA, including CD44v8-10 exon and flanking introns (500 bp each) was PCR amplified from the Human Genomic DNA Library (Promega, Madison, WI, USA). The PCR product was cloned into MluI and BamHI enzyme sites in pFlare9A-Dup34 vector. 28 Real-time PCR and run-off analysis Real-time PCR assay and primer sets for standard and variant exons were described previously. 3, 13 Run-off analysis was performed as described. 48, 49 Western blotting and immunoprecipitation
Western blot analysis of protein expression was described previously. were detected with corresponding primary monoclonal antibodies (1:1000 diluted in blocking buffer). For examining the effect of CD82 overexpression on U2AF2 ubiquitination, melanoma cells were treated with 10 μM MG132 for 6 h before U2AF2 was immunoprecipitated, resolved in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to a nitrocellulose membrane and developed with anti-ubiquitin P4D1 (1:1000, Santa Cruz) and anti-U2AF2 antibodies.
Immunofluorescence
Detailed procedure was described previously. 50 
Transwell migration
Transmigration was assessed by the ability of cells to migrate through a porous (8 μm) polycarbonate membrane of a transwell device (Corning, NY, USA) toward collagen IV. Migrated cells at the bottom of the filter were fixed with 4% formaldehyde and stained with 0.5% crystal violet.
Micropipette binding assay
A micropipette frequency assay to measure the binding affinity of tumor CD44 isoforms for E-selectin was described previously.
3,51,52
Flow migration assay
The assay was described previously. 1, 36 Briefly, a monolayer of Human umbilical vein endothelial cells was grown on polycarbonate filters (8 μm pore size; NeuroProbe, Gaithersburg, MD, USA). The center 12-wells of bottom plate were filled with collagen IV. Then, melanoma cells were drawn across HUVEC monolayer with a peristaltic pump at a shear flow (0.625 or 2 dyn/cm 2 ) for 4 h. Migrated cells were counted using an inverted microscope (IX71, Olympus, Melville, NY, USA ) with the NIH ImageJ software.
Statistical analysis
Data were obtained from at least three independent experiments and are expressed as means ± s.e.m. Statistical significance of differences was determined by Mann-Whitney U-test, Student's t-test or analysis of variance. Tukey's test was used for post-hoc analysis for analysis of variance. To assess the normal distribution and equal variance of the data, Kolmogorov-Smirnov and Levene tests were used. The correlation Figure 10 . Model of inhibition of U2AF2-dependent CD44 alternative splicing by CD82 in metastatic melanoma. Upper panel, in nonmetastatic melanoma, expression of CD82 induces ubiquitination and degradation of U2AF2, which leads to exon V8-10 skipping of CD44 pre-mRNA. Lower panel, loss of CD82 expression results in stabilization and binding of U2AF2 to 3'-splicing site of the intron adjacent to exon V8. This process facilitates exon V8-10 splicing, enhances the binding affinity of CD44 to E-selectin and promotes stress fiber formation and Src/FAK/RhoA activation, leading to increased motility and metastatic potential of melanoma.
